Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients

다국어 초록 (Multilingual Abstract)

Background: Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) is a protein with altered glycosylation that reacts with lectin, and was recently identified as a useful non-invasive biomarker for the diagnosis of liver fibrosis in patients with hepatitis C virus infection.This study aimed to evaluate the diagnostic efficacy of WFA-M2BP for liver fibrosis in the context of hepatitis B virus (HBV).
Methods: We enrolled 151 patients infected with HBV. Liver biopsy and elastography (Fibroscan) were performed during the initial visit. Fibrosis was graded according to the Knodell histologic activity index (F0–3). WFA-M2BP levels were determined with an automated immunoassay analyzer (M2BPGi, HISCL-5000, Sysmex, Japan). The diagnostic efficacy of WFA-M2BP was compared with those of various conventional or composite biomarkers, including enhanced liver fibrosis (ELF) score, Fibroscan, aspartate transaminase (AST)-toplatelet ratio index (APRI), and FIB-4, based on the area under the ROC curve (AUC) value.
Results: The majority of patients were at fibrosis stages F1 and F2. The F2 and F3 AUC values for WFA-M2BP were similar to those for FIB-4, APRI, ELF, and Fibroscan, although the latter showed the best diagnostic efficacy. The diagnostic accuracy of all tested biomarkers for F2 and F3 was 60–70%. In multivariate analysis, WFA-M2BP, ELF, and platelet count significantly predicted stage ≥F2, whereas only platelet count significantly predicted F3.
Conclusions: WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.

참고문헌 (Reference)

1 Ge PS, "Treatment of patients with Cirrhosis" 375 : 767-777, 2016

2 Li Q, "The gamma-glutamyltranspeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B" 95 : e3372-, 2016

3 Lichtinghagen R, "The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut off values" 59 : 236-242, 2013

4 Parkes J, "Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease" 11 : 1-20, 2012

5 Poynard T, "Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of liver fibrosis stages" 53 : 1615-1622, 2007

6 Rosenberg W, "Serum markers detect the presence of liver fibrosis: a cohort study" 127 : 1704-1713, 2004

7 Ichikawa Y, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection" 47 : 226-233, 2017

8 Zou X, "Serum $WFA^{+}$-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection" 37 : 35-44, 2017

9 Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (Fibroscan)" 53 : 885-894, 2011

10 Kim BK, "Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B" 7 : e41964-, 2012

11 Nobili V, "Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease" 136 : 160-167, 2009

12 Yoo EJ, "Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea" 33 : 706-713, 2013

13 Jang JW, "Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis" 61 : 1809-1820, 2015

14 Schuppan D, "Liver cirrhosis" 371 : 838-851, 2008

15 Theise N, "Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach" 20 : 3-14, 2007

16 Guechot J, "Independent validation of the enhanced liver fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C" 50 : 693-699, 2012

17 Brunt EM, "Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond" 31 : 241-246, 2000

18 Hanafiah KM, "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence" 57 : 1333-1342, 2013

19 Petruzziello A, "Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes" 22 : 7824-7840, 2016

20 CCLA, "Evaluation of precision performance of quantitative measurement methods; approved guideline, 3rd ed. NCCLS document EP5-A3"

21 Schweitzer A, "Estimation of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013" 386 : 1546-1555, 2015

22 Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients" 60 : 1563-1570, 2014

23 Kim YW, "Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C" 2104 : 210407-, 2014

24 Narimatsu H, "Development of WFA-M2BP: a novel fibrosis serum glycol-biomarker for chronic hepatitis/cirrhosis diagnostics" 12 : 683-693, 2015

25 Ellis E, "Clinical evidence for the regression of liver fibrosis" 56 : 1171-1180, 2012

26 Mallat A, "Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis" 305 : C789-C799, 2013

27 Castera L, "Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?" 59 : 861-866, 2010

28 Boursier J, "An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis test: The Liver-FibroSTARD standards" 62 : 807-815, 2015

29 Kuno A, "A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment I patients with viral hepatitis" 3 : 1065-, 2013

30 Nishikawa H, "A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation" 95 (95): e4679-, 2016

31 Ahmad W, "A brief review on molecule, genetic and imaging techniques for HCV fibrosis evaluation" 8 : 53-69, 2011